Phyla

About:

Phyla is developing alternative therapies for antibiotics.

Website: https://phylabiotics.com

Twitter/X: phylabiotics

Top Investors: Newchip Accelerator, Squared Circles, Joyance Partners, Willow Growth Partners, Progression Fund

Description:

Phyla is developing alternative therapies for antibiotics. The focus of most microbiome efforts is to discover beneficial bacteria to add to the microbiome, in order to cure disease or maintain health. However others lack a subtractive function that can remove harmful or disease-causing bacteria, that would allow the microbiome to rebalance and achieve a stable healthy state. Using bacteriophages as a foundation, they are developing a powerful platform that allows us to selectively 'subtract' bad bacteria without harming the good strains present in the community. It's a bit like using a sniper instead of a grenade to take out a bad guy in a crowd of people.

Total Funding Amount:

$3.24M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

San Francisco, California, United States

Founded Date:

2014-01-01

Contact Email:

info(AT)phitherapeutics.com

Founders:

Maria Cho, Yug Varma

Number of Employees:

1-10

Last Funding Date:

2023-12-07

IPO Status:

Private

Industries:

© 2025 bioDAO.ai